5 active trials 0 recruiting 1 Phase 3 7 disease areas 2 changes in 30 days
2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.
Completion pushed from Aug 31, 2026 to Feb 28, 2027
Daiichi Sankyo Co., Ltd.Phase 2 NCT04458272 Registry history of NCT04458272 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Jan 31, 2027 to Jan 31, 2031
Daiichi Sankyo Co., Ltd.Phase 2 NCT04433234 Registry history of NCT04433234 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 2 | |
| Phase 2 | 2 | |
| Phase 3 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT04488822 | A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT | Tenosynovial Giant Cell Tumor | Active, Not Recruiting | 2026-06-26 |
| Phase 2 | ||||
| NCT04433234 | Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Active, Not Recruiting | 2026-10-06 |
| NCT04458272 | A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated… | WHO Grade II Glioma | Active, Not Recruiting | 2026-10-06 |
| Phase 1 | ||||
| NCT03401385 | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | Hormone Receptor Positive Breast Cancer | Active, Not Recruiting | 2026-09-01 |
| NCT02732275 | DS-3201b in Participants With Lymphomas | Lymphoma, Malignant | Active, Not Recruiting | 2026-04-28 |
Breast Cancer (1) · Duchenne Muscular Dystrophy (1) · Glioma (1) · Lung Cancer (1) · Non-Hodgkin Lymphoma (1) · Non-Small Cell Lung Cancer (NSCLC) (1) · Triple-Negative Breast Cancer (1)